Medtronic (NYSE:MDT) Price Target Lowered to $100.00 at JPMorgan Chase & Co.

Medtronic (NYSE:MDT) had its target price cut by JPMorgan Chase & Co. from $105.00 to $100.00 in a research report released on Wednesday morning, Marketbeat reports. They currently have a neutral rating on the medical technology company’s stock.

Several other brokerages also recently issued reports on MDT. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. Citigroup began coverage on Medtronic in a report on Tuesday, February 3rd. They set a “buy” rating and a $117.00 price target on the stock. Wells Fargo & Company assumed coverage on Medtronic in a research report on Friday, January 30th. They set an “overweight” rating and a $114.00 price target on the stock. William Blair upgraded Medtronic from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 6th. Finally, Leerink Partners lowered their target price on Medtronic from $120.00 to $119.00 and set an “outperform” rating on the stock in a research note on Wednesday. Sixteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $111.05.

Medtronic Price Performance

MDT stock opened at $98.51 on Wednesday. Medtronic has a one year low of $79.55 and a one year high of $106.33. The firm has a 50-day moving average of $99.14 and a two-hundred day moving average of $96.59. The firm has a market capitalization of $126.29 billion, a PE ratio of 27.44, a P/E/G ratio of 2.54 and a beta of 0.71. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.88%. The firm’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, analysts forecast that Medtronic will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were paid a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is 76.55%.

Hedge Funds Weigh In On Medtronic

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MDT. Delos Wealth Advisors LLC acquired a new position in Medtronic during the 2nd quarter worth $27,000. Corundum Trust Company INC acquired a new position in shares of Medtronic during the 3rd quarter worth about $27,000. Lodestone Wealth Management LLC acquired a new stake in Medtronic in the 4th quarter valued at approximately $27,000. Anfield Capital Management LLC increased its position in Medtronic by 410.7% in the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after buying an additional 230 shares during the period. Finally, Valley Wealth Managers Inc. acquired a new position in shares of Medtronic during the third quarter worth approximately $29,000. Institutional investors own 82.06% of the company’s stock.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Q3 results beat consensus: Medtronic reported $9.0B in revenue and $1.36 non‑GAAP EPS, nudging past estimates as cardiovascular and diabetes growth led the quarter. This is the primary catalyst supporting the stock’s move. Medtronic beats quarterly profit estimates on robust demand for heart devices
• Positive Sentiment: Cardiac ablation and PFA strength: Cardiac Ablation Solutions grew ~80% (U.S. up ~137%), driven by pulsed field ablation — a clear growth engine for near‑term revenue expansion. Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters
• Positive Sentiment: FDA clearances and commercial milestones: The company secured FDA clearance for the Hugo™ RAS and reports the first U.S. surgical case; new device approvals and CE marks (e.g., Sphere‑360) support product pipeline upside. Medtronic announces first surgery with Hugo™ robotic-assisted surgery system in the U.S. performed at Cleveland Clinic
• Positive Sentiment: Commercial validation and adoption: Reports note U.S. cardiac ablations more than doubled and early commercial traction for Hugo in top centers — evidence of accelerating share gains in key markets. Medtronic U.S. cardiac ablations business more than doubled in Q3
• Neutral Sentiment: Guidance reaffirmed but conservative: Management reiterated FY26 guidance (EPS ~5.62–5.66), which was effectively in line with consensus — supportive but not a fresh upside catalyst. Medtronic PLC (MDT) Q3 2026 Earnings Call Highlights: Strong Cardiovascular Growth and …
• Positive Sentiment: M&A & pipeline moves: Recent bolt‑on deals (CathWorks, Anteris) and longer‑term robotics/structural‑heart catalysts bolster the multi‑year growth story investors are pricing in. Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters
• Negative Sentiment: Analysts trimming targets / forecasts: Multiple firms trimmed price targets (Leerink, JPMorgan, Baird) or adjusted models after Q3 — a headwind for near‑term sentiment even as ratings mostly remain Buy/Outperform. Leerink Partners adjusts price target on Medtronic to 119 from 120; maintains Outperform rating
• Negative Sentiment: Margin pressure and tariff impacts: Management noted cost and tariff pressures that compressed margins this quarter — a risk to near‑term profitability until cost levers or price actions offset them. Medtronic Profit Falls Despite Higher Revenue
• Neutral Sentiment: Technical/market narrative: MarketBeat and other commentary point to a bullish technical reversal and institutional accumulation — supportive for the stock if fundamentals remain intact, but tactical. Medtronic’s “Textbook” Reversal: How High Can It Really Go in 2026?

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).